ULTA
Wall Street’s Ulta obsession continues
Ulta Beauty got another round of analyst attention on April 18, and the vibe was basically: “same love, different spreadsheet.” Evercore, William Blair, Piper Sandler, and CCORF all updated their views, with targets ranging from $675 to $799.
The headline: still a buy, mostly
The most upbeat notes kept Ulta in the buy camp. Evercore’s Michael Binetti held a buy rating with a $675 target, while Piper Sandler’s Anna Andreeva also stayed bullish with a $725 target. CCORF went even higher, sticking with a buy and a $799 target. William Blair’s Dylan Carden was the outlier, keeping a hold rating.
Why investors should care
Analyst notes don’t move a stock by themselves forever, but they can matter when they reinforce the bigger story: how the market is thinking about Ulta’s growth, margins, and staying power in a beauty aisle that keeps getting more crowded. A cluster of buy ratings can act like a soft tailwind for sentiment — not rocket fuel, but not nothing either.
Big picture: Ulta’s still getting the “we like the setup” treatment from Wall Street, which is usually a decent sign the thesis hasn’t broken.